In a real-world study with 17,258 T2D patients who received dapagliflozin or other glucose-lowering agents, the albumin excretion rate was reduced in the dapagliflozin group and remained unchanged in the other groups. This evidence concerns the gene ALB and type 2 diabetes mellitus.